MCID: SKN022
MIFTS: 46

Skin Squamous Cell Carcinoma

Categories: Cancer diseases, Skin diseases

Aliases & Classifications for Skin Squamous Cell Carcinoma

MalaCards integrated aliases for Skin Squamous Cell Carcinoma:

Name: Skin Squamous Cell Carcinoma 12 15
Squamous Cell Carcinoma of Skin 12 73
Epidermoid Skin Carcinoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3151
NCIt 50 C4819
UMLS 73 C0553723

Summaries for Skin Squamous Cell Carcinoma

Disease Ontology : 12 A skin carcinoma that has material basis in squamous cells.

MalaCards based summary : Skin Squamous Cell Carcinoma, also known as squamous cell carcinoma of skin, is related to squamous cell carcinoma and palmoplantar hyperkeratosis with squamous cell carcinoma of skin and 46,xx sex reversal. An important gene associated with Skin Squamous Cell Carcinoma is TP53 (Tumor Protein P53), and among its related pathways/superpathways are Cytokine Signaling in Immune system and TNFR1 Pathway. The drugs Triamcinolone and Fluorouracil have been mentioned in the context of this disorder. Affiliated tissues include skin, lymph node and lung, and related phenotypes are cardiovascular system and cellular

Related Diseases for Skin Squamous Cell Carcinoma

Diseases related to Skin Squamous Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 88)
# Related Disease Score Top Affiliating Genes
1 squamous cell carcinoma 32.7 CDKN2A HRAS PIK3CA TP53
2 palmoplantar hyperkeratosis with squamous cell carcinoma of skin and 46,xx sex reversal 12.7
3 pseudovascular skin squamous cell carcinoma 12.3
4 acantholytic squamous cell skin carcinoma 11.8
5 epidermodysplasia verruciformis 11.5
6 clear cell squamous cell skin carcinoma 11.4
7 anal margin squamous cell carcinoma 11.3
8 melanomatosis 10.3 CDKN2A HRAS
9 bladder squamous cell carcinoma 10.3 CDKN2A TP53
10 keratinizing squamous cell carcinoma 10.2 CDKN2A TP53
11 adult hepatocellular carcinoma 10.2 PIK3CA TP53
12 rare adenocarcinoma of the breast 10.2 PIK3CA TP53
13 gallbladder adenoma 10.2 CDKN2A HRAS
14 malignant spiradenoma 10.2 PIK3CA TP53
15 apocrine adenoma 10.2 HRAS PIK3CA
16 bladder carcinoma in situ 10.2 CDKN2A TP53
17 vulva squamous cell carcinoma 10.2 CDKN2A TP53
18 ethmoid sinus cancer 10.2 HRAS PIK3CA
19 ethmoid sinus adenocarcinoma 10.2 HRAS PIK3CA
20 scrotal carcinoma 10.2 CDKN2A TP53
21 uterine corpus serous adenocarcinoma 10.2 PIK3CA TP53
22 aggressive digital papillary adenocarcinoma 10.2 HRAS PIK3CA
23 nasal cavity adenocarcinoma 10.2 CDKN2A HRAS TP53
24 biliary tract neoplasm 10.2 CDKN2A HRAS TP53
25 vulvar disease 10.2 CDKN2A TP53
26 serous cystadenocarcinoma 10.2 HRAS PIK3CA TP53
27 cell type benign neoplasm 10.2 CDKN2A HRAS TP53
28 cystadenocarcinoma 10.2 HRAS PIK3CA TP53
29 adenoid basal cell carcinoma 10.2 B2M CDKN2A
30 breast squamous cell carcinoma 10.2 PIK3CA TP53
31 anal squamous cell carcinoma 10.2 CDKN2A PIK3CA TP53
32 carcinosarcoma 10.2 HRAS PIK3CA TP53
33 penile cancer 10.2 CDKN2A PIK3CA TP53
34 endocrine gland cancer 10.2 CDKN2A HRAS TP53
35 ovary adenocarcinoma 10.2 HRAS PIK3CA TP53
36 uterine anomalies 10.2 CDKN2A PIK3CA TP53
37 spinal cancer 10.2 FAT2 TP53
38 transitional cell carcinoma 10.2 CDKN2A HRAS TP53
39 malignant ovarian surface epithelial-stromal neoplasm 10.2 HRAS PIK3CA TP53
40 ovary epithelial cancer 10.2 HRAS PIK3CA TP53
41 prostate adenoid cystic carcinoma 10.2 HRAS LRRC56 PIK3CA
42 renal cell carcinoma, papillary, 1 10.2 HRAS PIK3CA TP53
43 intestinal disease 10.2 HRAS PIK3CA TP53
44 uterine body mixed cancer 10.1 PIK3CA TP53
45 gastrointestinal system disease 10.1 CDKN2A HRAS TP53
46 suppression of tumorigenicity 12 10.1 HRAS PIK3CA TP53
47 pulmonic stenosis 10.1 HRAS LRRC56 MAP2K2
48 bartholin's gland disease 10.1 CDKN2A TP53
49 lung adenoid cystic carcinoma 10.1 HRAS PIK3CA
50 small cell cancer of the lung 10.1 CDKN2A PIK3CA TP53

Graphical network of the top 20 diseases related to Skin Squamous Cell Carcinoma:



Diseases related to Skin Squamous Cell Carcinoma

Symptoms & Phenotypes for Skin Squamous Cell Carcinoma

MGI Mouse Phenotypes related to Skin Squamous Cell Carcinoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.92 B2M CD151 CDKN2A HRAS MAP2K2 PIK3CA
2 cellular MP:0005384 9.91 B2M CD151 CDKN2A KLF4 MAP2K2 PATL2
3 endocrine/exocrine gland MP:0005379 9.81 B2M CDKN2A HRAS KLF4 MAP2K2 PATL2
4 integument MP:0010771 9.61 B2M CD151 CDKN2A HRAS KLF4 MAP2K2
5 neoplasm MP:0002006 9.23 B2M CD151 CDKN2A HRAS KLF4 MAP2K2

Drugs & Therapeutics for Skin Squamous Cell Carcinoma

Drugs for Skin Squamous Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 160)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Triamcinolone Approved, Vet_approved Phase 4,Phase 2 124-94-7 31307
2
Fluorouracil Approved Phase 4,Phase 2 51-21-8 3385
3
Acitretin Approved Phase 4,Phase 2,Not Applicable 55079-83-9 5284513 6437841
4 Immunologic Factors Phase 4,Phase 2,Phase 1,Not Applicable
5 Tin Fluorides Phase 4
6 Triamcinolone hexacetonide Phase 4,Phase 2
7 Antimetabolites, Antineoplastic Phase 4,Phase 2
8 Immunosuppressive Agents Phase 4,Phase 2,Phase 1,Not Applicable
9 Dermatologic Agents Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1
10 triamcinolone acetonide Phase 4,Phase 2
11 Antimetabolites Phase 4,Phase 3,Phase 2
12 Triamcinolone diacetate Phase 4,Phase 2
13 Hormones Phase 4,Phase 3,Phase 2
14 Hormone Antagonists Phase 4,Phase 3,Phase 2
15 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2
16 Keratolytic Agents Phase 4,Phase 2,Not Applicable
17
Carboplatin Approved Phase 3 41575-94-4 10339178 38904 498142
18
Darbepoetin alfa Approved, Investigational Phase 3 11096-26-7, 209810-58-2
19
Vemurafenib Approved Phase 3,Phase 1,Phase 2,Not Applicable 918504-65-1 23252090 42611257
20
Tamoxifen Approved Phase 3 10540-29-1 2733526
21
Anastrozole Approved, Investigational Phase 3 120511-73-1 2187
22
Pitavastatin Approved Phase 3 147511-69-1, 147526-32-7 5282452 6366718
23
Ornithine Approved, Nutraceutical Phase 3,Phase 2 3184-13-2, 70-26-8 6262
24
Citric Acid Approved, Nutraceutical, Vet_approved Phase 3 77-92-9 311
25 Anti-Infective Agents Phase 3,Phase 1,Phase 2
26 Antiparasitic Agents Phase 3,Phase 2,Phase 1
27 Antiprotozoal Agents Phase 3,Phase 2,Phase 1
28 Hematinics Phase 3
29 Bone Density Conservation Agents Phase 3
30 Estrogen Receptor Modulators Phase 3
31 Antineoplastic Agents, Hormonal Phase 3
32 Aromatase Inhibitors Phase 3
33 Steroid Synthesis Inhibitors Phase 3
34 Selective Estrogen Receptor Modulators Phase 3
35 Estrogen Antagonists Phase 3
36 Citrate Phase 3
37 Estrogens Phase 3
38 Estrogen Receptor Antagonists Phase 3
39 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 3
40 Anticholesteremic Agents Phase 3
41 Hypolipidemic Agents Phase 3
42 Lipid Regulating Agents Phase 3
43
Peginterferon alfa-2a Approved, Investigational Phase 1, Phase 2,Phase 2 198153-51-4 5360545
44
Gefitinib Approved, Investigational Phase 1, Phase 2,Phase 2 184475-35-2 123631
45
Dasatinib Approved, Investigational Phase 2 302962-49-8 3062316
46
Cetuximab Approved Phase 2,Phase 1,Not Applicable 205923-56-4 56842117 2333
47
Aminolevulinic acid Approved Phase 2,Not Applicable,Early Phase 1 106-60-5 137
48
Aldesleukin Approved Phase 1, Phase 2 85898-30-2, 110942-02-4
49
Isotretinoin Approved Phase 2,Not Applicable 4759-48-2 5538 5282379
50
Pembrolizumab Approved Phase 2,Phase 1 1374853-91-4

Interventional clinical trials:

(show top 50) (show all 109)
# Name Status NCT ID Phase Drugs
1 CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial Completed NCT00847912 Phase 4 5-fluorouracil;Placebo, vehicle control
2 Long-Term Growth and Skeletal Effects of Early Growth Hormone Treatment in Turner Syndrome Completed NCT00266656 Phase 4 Humatrope
3 Acitretin Plasma Levels Under Hemodialysis Withdrawn NCT00488384 Phase 4 Chemopreventive application (Acitretin)
4 Post-operative Concurrent Chemo-radiotherapy Versus Post-operative Radiotherapy for Cancer of the Head and Neck Completed NCT00193895 Phase 3 Carboplatin
5 Eflornithine to Prevent Skin Cancer in Patients With Previously Treated Early Stage Skin Cancer Completed NCT00005884 Phase 3 eflornithine
6 Radiation Therapy in Treating Patients With Head and Neck Cancer Completed NCT00021125 Phase 3
7 Darbepoetin Alfa in Patients With Anemic Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) Completed NCT01362140 Phase 3 Darbepoetin alfa;Placebo
8 A Study of Vemurafenib in Participants With Metastatic Melanoma Completed NCT01307397 Phase 3 Vemurafenib
9 Anastrozole or Tamoxifen in Treating Postmenopausal Women With Ductal Carcinoma in Situ Who Are Undergoing Lumpectomy and Radiation Therapy Completed NCT00053898 Phase 3 anastrozole;tamoxifen citrate
10 Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults Recruiting NCT02344290 Phase 3 Pitavastatin;Placebo
11 Efficacy and Safety of Dacomitinib in the Treatment of Skin Squamous Cell Cancer Unknown status NCT02268747 Phase 2 Dacomitinib
12 Panitumumab (Vectibix®) in Cutaneous Squamous Cell Carcinoma (SCC) Unknown status NCT01129154 Phase 2 infusions of Panitumumab
13 Gefitinib and PEG-Interferon Alfa-2a in Treating Patients With Unresectable or Metastatic Skin Cancer Unknown status NCT00423397 Phase 1, Phase 2 gefitinib
14 Low Fat Diet to Prevent Disease Progression in Patients With Skin Cancer Unknown status NCT00003097 Phase 2
15 Safety, Tolerability, and Efficacy Study of CLL442 in Patients With Cutaneous Squamous Cell Carcinoma in Situ (SCCis) Completed NCT03333694 Phase 1, Phase 2 Cutaneous Cream application;Placebo Cutaneous Cream application
16 Gefitinib in Treating Patients Who Are Undergoing Surgery and/or Radiation Therapy for Locally Advanced or Recurrent Squamous Cell Skin Cancer Completed NCT00126555 Phase 2 Gefitinib
17 Dasatinib in Treating Patients With Unresectable or Metastatic Squamous Cell Skin Cancer or RAI Stage 0-I Chronic Lymphocytic Leukemia Completed NCT00563290 Phase 2 dasatinib
18 An Open-Label Safety Study of API 31510 in a Topical Cream for in Situ Cutaneous Squamous Cell Carcinoma (SCCIS) Completed NCT00652080 Phase 1, Phase 2 API 31510
19 Study to Determine the Safety of Two Applications of PEP005 Topical Gel to Cutaneous Squamous Cell Carcinoma In Situ Completed NCT00329121 Phase 2 PEP005
20 Study of Cetuximab in Squamous Cell Carcinoma of the Skin Expressing EGFR Completed NCT00240682 Phase 2 cetuximab
21 ZD1839 (Iressa) for Recurrent or Metastatic Squamous Cell Carcinoma of the Skin Completed NCT00054691 Phase 2 Iressa
22 A Trial of Erlotinib + Radiotherapy for Cutaneous Squamous Cell Carcinoma Completed NCT00369512 Phase 2 Erlotinib
23 Clinical Study Assessment of SR-T100 Topical Gel Against Actinic Keratosis Completed NCT02085395 Phase 2 SR-T100 ® Gel
24 Photodynamic Therapy in Treating Patients With Skin Cancer Completed NCT00002963 Phase 2 aminolevulinic acid hydrochloride
25 Effect of Solanum Melongena Extract in the Treatment of Arsenical Skin Lesion Completed NCT03127670 Phase 2 Solanum melongena peel extract 0.05%
26 Eflornithine With or Without Triamcinolone in Preventing Nonmelanoma Skin Cancer in Patients With Actinic Keratosis Completed NCT00021294 Phase 2 eflornithine;triamcinolone
27 Photodynamic Therapy in Treating Patients With Skin Cancer Completed NCT00002975 Phase 2 aminolevulinic acid
28 Investigation of a Behavioral Substitute for Sunbathing Completed NCT00403377 Phase 1, Phase 2
29 T4N5 Liposomal Lotion in Preventing The Recurrence of Nonmelanoma Skin Cancer in Patients Who Have Undergone a Kidney Transplant Completed NCT00089180 Phase 2 liposomal T4N5 lotion
30 Systemic Therapy With Interferon, Interleukin-2 and BRAF Inhibitor Completed NCT01603212 Phase 1, Phase 2 Vemurafenib;IL-2;Interferon Alpha-2b
31 Oral Rigosertib for Squamous Cell Carcinoma Completed NCT01807546 Phase 2 rigosertib
32 SU5416 in Treating Patients With Advanced or Recurrent Cancer of the Head and Neck Completed NCT00006361 Phase 2 semaxanib
33 Isotretinoin Plus Interferon in Treating Patients With Recurrent Cancer Completed NCT00002506 Phase 2 isotretinoin
34 Study of REGN2810 in Patients With Advanced Cutaneous Squamous Cell Carcinoma Recruiting NCT02760498 Phase 2 cemiplimab
35 Study of Pembrolizumab (MK-3475) in Adults With Recurrent/Metastatic Cutaneous Squamous Cell Carcinoma (cSCC) or Locally Advanced Unresectable cSCC (MK-3475-629/KEYNOTE-629) Recruiting NCT03284424 Phase 2
36 Pembrolizumab in Patients With Locally Advanced or Metastatic Skin Cancer Recruiting NCT02964559 Phase 2
37 Cemiplimab in Treating Participants With Recurrent Stage III-IV Head and Neck Squamous Cell Cancer Before Surgery Recruiting NCT03565783 Phase 2
38 Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers Recruiting NCT02978625 Phase 2
39 Cobimetinib and Atezolizumab in Advanced Rare Tumors Recruiting NCT03108131 Phase 2 Cobimetinib;Atezolizumab
40 Study of TVEC in Patients With Cutaneous Squamous Cell Cancer Recruiting NCT03714828 Phase 2 Injection of TVEC into target lesions - week 1-2;Injection of TVEC into target lesions 3wks after 1st injection;Injection of TVEC into target lesions 2wks after 2nd injection;Injection of TVEC into target lesions 2wks after 3rd injection
41 Intratumoral AST-008 Combined With Pembrolizumab in Patients With Advanced Solid Tumors Recruiting NCT03684785 Phase 1, Phase 2 AST-008
42 Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic Recruiting NCT02721732 Phase 2
43 CIMAvax Vaccine, Nivolumab, and Pembrolizumab in Treating Patients With Advanced Non-small Cell Lung Cancer or Squamous Head and Neck Cancer Recruiting NCT02955290 Phase 1, Phase 2
44 Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma Recruiting NCT03082534 Phase 2 Pembrolizumab, Cetuximab
45 Erlotinib in Treating Patients With Recurrent or Metastatic Skin Squamous Cell Carcinoma Active, not recruiting NCT01198028 Phase 2 Erlotinib
46 Capecitabine or 5-FU With Pegylated Interferon Alpha-2b in Unresectable/Metastatic Cutaneous Squamous Cell Carcinoma Active, not recruiting NCT02218164 Phase 2 Pegylated Interferon alpha-2b;Capecitabine;5-FU
47 Study of Pembrolizumab as First Line Therapy in Patients With Unresectable Squamous Cell Carcinoma of the Skin Active, not recruiting NCT02883556 Phase 2 Pembrolizumab
48 Post-operative Radiation With Cetuximab for Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck Active, not recruiting NCT01979211 Phase 2 Cetuximab
49 Preventing Squamous Cell Skin Cancer Enrolling by invitation NCT02347813 Phase 2 Pioglitazone
50 The UNSCARRed Study: UNresctable Squamous Cell Carcinoma Treated With Avelumab and Radical Radiotherapy Not yet recruiting NCT03737721 Phase 2

Search NIH Clinical Center for Skin Squamous Cell Carcinoma

Genetic Tests for Skin Squamous Cell Carcinoma

Anatomical Context for Skin Squamous Cell Carcinoma

MalaCards organs/tissues related to Skin Squamous Cell Carcinoma:

41
Skin, Lymph Node, Lung, T Cells, Monocytes, Ovary, Prostate

Publications for Skin Squamous Cell Carcinoma

Articles related to Skin Squamous Cell Carcinoma:

(show top 50) (show all 100)
# Title Authors Year
1
Gadd45a gene silencing by RNAi promotes cell proliferation and inhibits apoptosis and senescence in skin squamous cell carcinoma through the p53 signaling pathway. ( 29663367 )
2018
2
Targeting sphingosine kinase 2 by ABC294640 inhibits human skin squamous cell carcinoma cell growth. ( 29428730 )
2018
3
IGF2BP1 over-expression in skin squamous cell carcinoma cells is essential for cell growth. ( 29753746 )
2018
4
Inhibitory effect of microRNA-154 targeting WHSC1 on cell proliferation of human skin squamous cell carcinoma through mediating the P53 signaling pathway. ( 29727714 )
2018
5
Bromodomain protein BRD4 promotes cell proliferation in skin squamous cell carcinoma. ( 29050985 )
2018
6
Antitumor Effects of DC Vaccine With ALA-PDT-Induced Immunogenic Apoptotic Cells for Skin Squamous Cell Carcinoma in Mice. ( 30025490 )
2018
7
Correlation between tripartite motif-containing protein 44 protein expression and the prognosis of postoperative patients exhibiting skin squamous cell carcinoma. ( 30383661 )
2018
8
Targeting PI3K-AKT-mTOR by LY3023414 inhibits human skin squamous cell carcinoma cell growth inA vitro and inA vivo. ( 28623128 )
2017
9
Lgr6 is a stem cell marker in mouse skin squamous cell carcinoma. ( 28945253 )
2017
10
CCR5-dependent homing of T regulatory cells to the tumor microenvironment contributes to skin squamous cell carcinoma development. ( 28904130 )
2017
11
A case report of Muir-Torre syndrome in a woman with breast cancer and MSI-Low skin squamous cell carcinoma. ( 28507641 )
2017
12
Antimicrobial peptide LL-37 promotes the viability and invasion of skin squamous cell carcinoma by upregulating YB-1. ( 28672959 )
2017
13
Quantitative phosphoproteomic analysis reveals system-wide signaling pathways regulated by site-specific phosphorylation of Keratin-8 in skin squamous cell carcinoma derived cell line. ( 28176443 )
2017
14
Correlation Between Microvessel Density and Morphological Features in Skin Squamous Cell Carcinoma. ( 28593886 )
2017
15
Cancer cell of origin controls epithelial-to-mesenchymal transition in skin squamous cell carcinoma. ( 28607908 )
2017
16
An Investigative Approach to Treatment Modalities for Squamous Cell Carcinoma of Skin. ( 27601059 )
2017
17
Squamous Cell Carcinoma of Skin after 20 Years of Renal Transplantation. ( 29217883 )
2017
18
DC vaccine generated by ALA-PDT-induced immunogenic apoptotic cells for skin squamous cell carcinoma. ( 27471605 )
2016
19
The genetic evolution of skin squamous cell carcinoma: tumor suppressor identity matters. ( 27193637 )
2016
20
Predicted cases of U.K. skin squamous cell carcinoma and basal cell carcinoma in 2020 and 2025: horizon planning for National Health Service dermatology and dermatopathology. ( 27714753 )
2016
21
Erratum: Genomic landscape of carcinogen-induced and genetically induced mouse skin squamous cell carcinoma. ( 26845409 )
2016
22
Antimicrobial peptide LL-37 promotes the proliferation and invasion of skin squamous cell carcinoma by upregulating DNA-binding protein A. ( 27588122 )
2016
23
Inhibitory effect of berberine on human skin squamous cell carcinoma A431 cells. ( 26400287 )
2015
24
Efficacy of elective nodal irradiation in skin squamous cell carcinoma of the face, ears, and scalp. ( 26391010 )
2015
25
TIPE2 regulates tumor-associated macrophages in skin squamous cell carcinoma. ( 26577853 )
2015
26
Skin squamous cell carcinoma presenting as cellulitis. ( 25635168 )
2015
27
Inhibitory effect of curcumin on invasion of skin squamous cell carcinoma a431 cells. ( 25854367 )
2015
28
Exposure to moxifloxacin and cytomegalovirus replication is associated with skin squamous cell carcinoma development in lung transplant recipients. ( 26403508 )
2015
29
Inhibition of skin squamous cell carcinoma proliferation and promote apoptosis by dual silencing of NET-1 and survivin. ( 26080853 )
2015
30
Ginsenoside rh2 inhibits cancer stem-like cells in skin squamous cell carcinoma. ( 25966742 )
2015
31
Clinical significance of STAT3 and MAPK phosphorylation, and the protein expression of cyclin D1 in skin squamous cell carcinoma tissues. ( 26497194 )
2015
32
Improvement of DC vaccine with ALA-PDT induced immunogenic apoptotic cells for skin squamous cell carcinoma. ( 25915530 )
2015
33
Genomic landscape of carcinogen-induced and genetically induced mouse skin squamous cell carcinoma. ( 26168291 )
2015
34
Denosumab Therapy for Refractory Hypercalcemia Secondary to Squamous Cell Carcinoma of Skin in Epidermolysis Bullosa. ( 29147430 )
2015
35
Autophagy in human skin squamous cell carcinoma: Inhibition by 3-MA enhances the effect of 5-FU-induced chemotherapy sensitivity. ( 26398820 )
2015
36
A rare collision tumour of infiltrating ductal carcinoma and squamous cell carcinoma of skin overlying breast: a case report. ( 25738072 )
2015
37
Myiasis on squamous cell carcinoma of skin. ( 25387871 )
2014
38
Lgr5-positive cells are cancer stem cells in skin squamous cell carcinoma. ( 25135431 )
2014
39
Lung transplant recipients receiving voriconazole and skin squamous cell carcinoma risk in Australia. ( 25358582 )
2014
40
Clinical significance of methylation of E-cadherin and p14ARF gene promoters in skin squamous cell carcinoma tissues. ( 25126184 )
2014
41
Advanced skin squamous cell carcinoma: role of radiotherapy. ( 24563891 )
2014
42
Aldo-keto reductase 1C3 is overexpressed in skin squamous cell carcinoma (SCC) and affects SCC growth via prostaglandin metabolism. ( 24917395 )
2014
43
Sox2, a marker for stem-like tumor cells in skin squamous cell carcinoma and hedgehog subgroup medulloblastoma. ( 25061226 )
2014
44
Hypertrophic lichen planus mimicking squamous cell carcinoma of skin. ( 25170045 )
2014
45
The inhibition of resveratrol to human skin squamous cell carcinoma A431 xenografts in nude mice. ( 23428654 )
2013
46
Immunohistochemical analysis of O(6)-methylguanine-DNA methyltransferase in human melanoma in comparison with skin squamous cell carcinoma. ( 23460078 )
2013
47
Tetraspanin CD151 plays a key role in skin squamous cell carcinoma. ( 22824799 )
2013
48
Expression and function of NET-1 in human skin squamous cell carcinoma. ( 24196235 )
2013
49
HPV type 16-induced skin squamous cell carcinoma located on the groin of immunocompetent patients. ( 24116660 )
2013
50
Squamous cell carcinoma of skin: a brief review. ( 23698209 )
2013

Variations for Skin Squamous Cell Carcinoma

Cosmic variations for Skin Squamous Cell Carcinoma:

9 (show top 50) (show all 6898)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM4990875 ZNF668 skin,NS,carcinoma,squamous cell carcinoma c.247C>T p.P83S 16:31064213-31064213 13
2 COSM703213 ZNF668 skin,NS,carcinoma,squamous cell carcinoma c.1817C>T p.P606L 16:31061111-31061111 13
3 COSM4990873 ZNF668 skin,NS,carcinoma,squamous cell carcinoma c.878C>T p.S293L 16:31062050-31062050 13
4 COSM4990309 ZMYM2 skin,NS,carcinoma,squamous cell carcinoma c.946C>T p.Q316* 13:20002948-20002948 13
5 COSM4990310 ZMYM2 skin,NS,carcinoma,squamous cell carcinoma c.946C>T p.Q316* 13:20002948-20002948 13
6 COSM4991869 ZIC4 skin,NS,carcinoma,squamous cell carcinoma c.282C>G p.A94A 3:147396258-147396258 13
7 COSM4991865 ZIC4 skin,NS,carcinoma,squamous cell carcinoma c.522C>T p.F174F 3:147396018-147396018 13
8 COSM4991861 ZIC4 skin,NS,carcinoma,squamous cell carcinoma c.876G>C p.P292P 3:147391059-147391059 13
9 COSM4991863 ZIC4 skin,NS,carcinoma,squamous cell carcinoma c.569A>C p.K190T 3:147395971-147395971 13
10 COSM4991867 ZIC4 skin,NS,carcinoma,squamous cell carcinoma c.314T>G p.V105G 3:147396226-147396226 13
11 COSM4990301 ZIC2 skin,NS,carcinoma,squamous cell carcinoma c.915G>A p.E305E 13:99982979-99982979 13
12 COSM3184673 ZFP36L2 skin,NS,carcinoma,squamous cell carcinoma c.569C>T p.P190L 2:43225235-43225235 13
13 COSM3184669 ZFP36L2 skin,NS,carcinoma,squamous cell carcinoma c.596C>T p.T199I 2:43225208-43225208 13
14 COSM6963526 ZFHX3 skin,NS,carcinoma,squamous cell carcinoma c.1646C>T p.S549F 16:72958500-72958500 13
15 COSM6974401 ZFHX3 skin,NS,carcinoma,squamous cell carcinoma c.2933C>T p.A978V 16:72950752-72950752 13
16 COSM6934239 ZFHX3 skin,NS,carcinoma,squamous cell carcinoma c.10688G>A p.R3563K 16:72787588-72787588 13
17 COSM6934240 ZFHX3 skin,NS,carcinoma,squamous cell carcinoma c.727G>A p.D243N 16:72959419-72959419 13
18 COSM6926616 ZFHX3 skin,NS,carcinoma,squamous cell carcinoma c.10999G>A p.D3667N 16:72787277-72787277 13
19 COSM6944080 ZFHX3 skin,NS,carcinoma,squamous cell carcinoma c.1138C>T p.P380S 16:72959008-72959008 13
20 COSM6926265 ZFHX3 skin,NS,carcinoma,squamous cell carcinoma c.10577G>A p.G3526D 16:72787699-72787699 13
21 COSM6944931 ZFHX3 skin,NS,carcinoma,squamous cell carcinoma c.7759C>T p.Q2587* 16:72794923-72794923 13
22 COSM4991542 ZBED4 skin,NS,carcinoma,squamous cell carcinoma c.328C>T p.R110W 22:49883990-49883990 13
23 COSM4993525 ZBED1 skin,NS,carcinoma,squamous cell carcinoma c.601T>G p.W201G 23:2490119-2490119 13
24 COSM228200 YES1 skin,NS,carcinoma,squamous cell carcinoma c.1499C>T p.S500F 18:724557-724557 13
25 COSM6932261 YES1 skin,NS,carcinoma,squamous cell carcinoma c.373G>A p.E125K 18:748017-748017 13
26 COSM6982918 YES1 skin,NS,carcinoma,squamous cell carcinoma c.851G>A p.G284E 18:743289-743289 13
27 COSM6932242 YAP1 skin,NS,carcinoma,squamous cell carcinoma c.938C>T p.S313F 11:102223689-102223689 13
28 COSM4991780 XPO1 skin,NS,carcinoma,squamous cell carcinoma c.2285G>A p.W762* 2:61488193-61488193 13
29 COSM4829120 XPC skin,NS,carcinoma,squamous cell carcinoma c.1439C>T p.S480F 3:14158444-14158444 13
30 COSM4991848 XPC skin,NS,carcinoma,squamous cell carcinoma c.2255C>T p.P752L 3:14148727-14148727 13
31 COSM4991849 XPC skin,NS,carcinoma,squamous cell carcinoma c.2254C>T p.P752S 3:14148728-14148728 13
32 COSM4991847 XPC skin,NS,carcinoma,squamous cell carcinoma c.2445G>A p.E815E 3:14147977-14147977 13
33 COSM4991846 XPC skin,NS,carcinoma,squamous cell carcinoma c.2446G>A p.E816K 3:14147976-14147976 13
34 COSM28974 WT1 skin,NS,carcinoma,squamous cell carcinoma c.935G>A p.R312Q 11:32396367-32396367 13
35 COSM4990181 WT1 skin,NS,carcinoma,squamous cell carcinoma c.726C>A p.N242K 11:32417597-32417597 13
36 COSM6939000 WT1 skin,NS,carcinoma,squamous cell carcinoma c.1046-1G>T p.? 11:32392756-32392756 13
37 COSM6917498 WT1 skin,NS,carcinoma,squamous cell carcinoma c.1034G>A p.R345K 11:32396268-32396268 13
38 COSM6884834 WT1 skin,NS,carcinoma,squamous cell carcinoma c.964C>T p.P322S 11:32396338-32396338 13
39 COSM4990704 VTI1B skin,NS,carcinoma,squamous cell carcinoma c.274C>T p.H92Y 14:67659823-67659823 13
40 COSM6909326 VTCN1 skin,NS,carcinoma,squamous cell carcinoma c.137G>A p.G46E 1:117156882-117156882 13
41 COSM6909324 VTCN1 skin,NS,carcinoma,squamous cell carcinoma c.610G>A p.E204K 1:117153205-117153205 13
42 COSM6972902 VTCN1 skin,NS,carcinoma,squamous cell carcinoma c.134C>T p.A45V 1:117156885-117156885 13
43 COSM6912242 VTCN1 skin,NS,carcinoma,squamous cell carcinoma c.628G>A p.V210I 1:117153187-117153187 13
44 COSM6967157 VTCN1 skin,NS,carcinoma,squamous cell carcinoma c.236T>A p.L79* 1:117156783-117156783 13
45 COSM14356 VHL skin,NS,carcinoma,squamous cell carcinoma c.394C>T p.Q132* 3:10146567-10146567 13
46 COSM30228 VHL skin,NS,carcinoma,squamous cell carcinoma c.337C>T p.R113* 3:10142184-10142184 13
47 COSM6937204 VEGFA skin,NS,carcinoma,squamous cell carcinoma c.701C>T p.P234L 6:43777511-43777511 13
48 COSM4991824 UMPS skin,NS,carcinoma,squamous cell carcinoma c.332G>A p.G111E 3:124737589-124737589 13
49 COSM4991823 UMPS skin,NS,carcinoma,squamous cell carcinoma c.331G>A p.G111R 3:124737588-124737588 13
50 COSM4991826 UMPS skin,NS,carcinoma,squamous cell carcinoma c.843G>A p.K281K 3:124738100-124738100 13

Expression for Skin Squamous Cell Carcinoma

Search GEO for disease gene expression data for Skin Squamous Cell Carcinoma.

Pathways for Skin Squamous Cell Carcinoma

Pathways related to Skin Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 93)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.35 B2M HRAS MAP2K2 PIK3CA STAT2 TP53
2
Show member pathways
12.95 HRAS MAP2K2 PIK3CA RAC1 TP53
3
Show member pathways
12.95 HRAS MAP2K2 PIK3CA RAC1 STAT2 TP53
4
Show member pathways
12.91 HRAS MAP2K2 PIK3CA RAC1 TP53
5
Show member pathways
12.91 HRAS MAP2K2 RAC1 STAT2 TP53
6
Show member pathways
12.79 CDKN2A HRAS MAP2K2 PIK3CA TP53
7
Show member pathways
12.79 CDKN2A HRAS MAP2K2 PIK3CA RAC1 TP53
8
Show member pathways
12.75 CDKN2A HRAS MAP2K2 PIK3CA TP53
9
Show member pathways
12.74 CDKN2A HRAS MAP2K2 PIK3CA TP53
10
Show member pathways
12.69 HRAS MAP2K2 PIK3CA RAC1 TP53
11 12.63 CDKN2A HRAS MAP2K2 PIK3CA RAC1 STAT2
12
Show member pathways
12.62 HRAS MAP2K2 PIK3CA RAC1
13 12.62 HRAS MAP2K2 PIK3CA RAC1
14
Show member pathways
12.58 HRAS PIK3CA RAC1 TP53
15
Show member pathways
12.58 HRAS MAP2K2 PIK3CA RAC1
16
Show member pathways
12.56 HRAS MAP2K2 PIK3CA RAC1
17
Show member pathways
12.52 HRAS MAP2K2 PIK3CA RAC1
18
Show member pathways
12.51 HRAS MAP2K2 PIK3CA RAC1
19
Show member pathways
12.5 HRAS MAP2K2 PIK3CA RAC1 TP53
20
Show member pathways
12.48 HRAS MAP2K2 PIK3CA RAC1
21 12.47 CDKN2A HRAS MAP2K2 PIK3CA TP53
22
Show member pathways
12.44 HRAS MAP2K2 PIK3CA RAC1
23
Show member pathways
12.44 HRAS MAP2K2 PIK3CA RAC1 TP53
24
Show member pathways
12.43 HRAS MAP2K2 PIK3CA TP53
25 12.42 CDKN2A HRAS PIK3CA TP53
26
Show member pathways
12.41 HRAS MAP2K2 PIK3CA RAC1
27
Show member pathways
12.4 HRAS MAP2K2 PIK3CA STAT2
28
Show member pathways
12.4 HRAS MAP2K2 PIK3CA RAC1
29
Show member pathways
12.39 HRAS MAP2K2 PIK3CA RAC1
30
Show member pathways
12.39 HRAS MAP2K2 PIK3CA TP53
31
Show member pathways
12.37 HRAS MAP2K2 PIK3CA RAC1
32
Show member pathways
12.32 HRAS MAP2K2 PIK3CA RAC1
33
Show member pathways
12.31 HRAS MAP2K2 PIK3CA RAC1
34
Show member pathways
12.31 HRAS MAP2K2 PIK3CA RAC1
35
Show member pathways
12.25 HRAS MAP2K2 RAC1 TP53
36
Show member pathways
12.25 HRAS MAP2K2 PIK3CA RAC1 STAT2 TP53
37
Show member pathways
12.24 HRAS MAP2K2 PIK3CA RAC1 TP53
38 12.21 B2M PIK3CA RAC1 STAT2 TP53
39
Show member pathways
12.2 HRAS MAP2K2 PIK3CA TP53
40
Show member pathways
12.2 HRAS MAP2K2 PIK3CA STAT2
41 12.2 HRAS MAP2K2 PIK3CA RAC1 TP53
42 12.18 CDKN2A HRAS PIK3CA RAC1 TP53
43
Show member pathways
12.15 HRAS MAP2K2 PIK3CA TP53
44
Show member pathways
12.13 HRAS MAP2K2 RAC1 TP53
45
Show member pathways
12.12 HRAS MAP2K2 PIK3CA RAC1
46
Show member pathways
12.11 B2M CDKN2A HRAS MAP2K2 PIK3CA RAC1
47 12.09 PIK3CA RAC1 TP53
48
Show member pathways
12.09 HRAS MAP2K2 PIK3CA
49
Show member pathways
12.07 HRAS MAP2K2 PIK3CA
50
Show member pathways
12.07 HRAS MAP2K2 PIK3CA STAT2

GO Terms for Skin Squamous Cell Carcinoma

Cellular components related to Skin Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 focal adhesion GO:0005925 8.92 B2M CD151 MAP2K2 RAC1

Biological processes related to Skin Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription, DNA-templated GO:0045893 9.55 CDKN2A KLF4 MAP2K2 TP53 TRIM44
2 cell cycle arrest GO:0007050 9.5 CDKN2A HRAS TP53
3 replicative senescence GO:0090399 9.26 CDKN2A TP53
4 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 8.96 MAP2K2 TP53
5 Ras protein signal transduction GO:0007265 8.8 CDKN2A HRAS TP53

Molecular functions related to Skin Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 histone deacetylase binding GO:0042826 8.8 KLF4 RAC1 TP53

Sources for Skin Squamous Cell Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....